Tocomin®SupraBio™ to be Used in Largest Clinical Trial on Tocotrienols - Neuroprotective & Anti-Athe
Carotech announces the starting of the largest phase II clinical trial on tocotrienols that evaluates the neuroprotective and anti-atherogenic functions of Tocomin®SupraBio™.
[ClickPress, Wed Sep 23 2009] Carotech is pleased to announce the commencement of the largest human clinical trial on tocotrienols, specifically evaluating the neuroprotective and anti-atherogenic properties of Tocomin®SupraBio™ – patented and bioenhanced natural full spectrum palm tocotrienol complex.
It is a 3-year randomized double blind placebo controlled study involving 400 subjects and funded by the Malaysian Palm Oil Board and the Ministry of Science, Malaysia. Carotech provides all the soft gel capsules (based on Tocomin®SupraBio™) for this study.
This phase II clinical trial evaluates the neuroprotective properties of Tocomin®SupraBio™ by evaluating and reviewing white matter changes in the brain using magnetic resonance imaging (MRI) before, during and after supplementation. White matter lesions represent areas of subclinical infarct and may be an independent prognostic measure of future stroke risk.
Large animal studies conducted by Prof. Chandan Sen and his group of researchers at The Ohio State University Medical Center showed extremely low level of Tocomin® natural full spectrum palm tocotrienol complex prevented glutamate-induced death of neuron cells in mice through the inhibition of c-Src kinase and 12-lipoxygenase. In addition, tocotrienol-supplemented rats showed more protection against stroke-induced injury (significant reduction in volume of cerebral infarct) compared with matched controls.
In addition to the neuroprotective effect, the study will also evaluate the effects of tocotrienols on blood parameters such as total lipid profile, Apo-B, C-reactive protein, antioxidant profile, Lp(a) and lipid peroxidation (secondary objectives).
"We are proud to be chosen and associated with this largest ever clinical trial on tocotrienols. Being the largest and only GMP-certified tocotrienol producer, it underscores Carotech’s emphasis on science and clinical trials to bring this unique form of vitamin E to our customers." says WH Leong, the Vice President of Carotech Inc.
"Tocomin®SupraBio™ is a patented self-emulsifying tocotrienol formulation that enhances oral absorption of tocotrienols by an average of 250% and independent of food intake," adds WH Leong.
About Carotech Ltd
Carotech Berhad, incorporated in 1990, is a public listed company in Malaysia (ACE Market, formerly MESDAQ Board). It is the first and largest producer of natural full spectrum tocotrienol complex (Tocomin® & Tocomin® SupraBio™), natural mixed carotene complex (Caromin®) and phytosterol complex (Stelessterol™) in the world via its patented technology.
Carotech is the only GMP-Certified tocotrienol producer in the world.
Carotech is a subsidiary of Hovid Ltd (www.hovid.com), one of the largest GMP-certified pharmaceutical companies in Malaysia.
Carotech manufactures these products under the tradenames : Tocomin®, Tocomin®SupraBio™, Caromin® and Stelessterol™.
Tocomin®SupraBio™, the main active ingredient used in Tocovid™SupraBio™, is a patented (US Patent No. 6,596,306) self emulsifying palm tocotrienol complex that ensures optimal tocotrienols oral absorption.
Websites : www.carotech.net and www.tocotrienol.org
Carotech Inc, Edison, NJ
Tel : +1 732 906 1901
firstname.lastname@example.org or email@example.com